

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 20-2-2008

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 22-12-2007 TO BE PUBLISHED ON 20-2-2008 IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

<u>17-12-2007</u>		
1489/2007	NeuroSearch A/S. Denmark. Priority (20-12-06 Denmark)	“Novel compounds”
1490/2007	Novartis AG. Switzerland. Priority (20-12-06 EP)	“Pharmaceutical compositions”
1491/2007	Smithkline Beecham Corporation. USA. Priority (18-12-06 USA)	“Calcilytic compounds”
1492/2007	Pioneer Hi-Bred International, Inc. USA. Priority (26-06-07 USA)	“Novel bacillus thuringiensis gene with lepidopteran activity”
1493/2007	Takeda Pharmaceutical Company Limited. Japan. Priority (18-12-06 USA)	“Sustained-release composition and method for producing the same”
1494/2007	Schering Corporation. USA. Priority (22-12-06 USA)	“4,5-ring annulated indole derivatives and methods of use thereof”
1495/2007	Schering Corporation. USA. Priority (22-12-06 USA)	“4,5-ring annulated indole derivatives and methods of use thereof”
1496/2007	Schering Corporation. USA. Priority (22-12-06 USA)	“4,5-ring annulated indole derivatives and methods of use thereof”
<u>18-12-2007</u>		
1497/2007	Dr. Mansoor Ahmad. Karachi-Pakistan.	“Herbal remedy against sexual dysfunction”
1498/2007	Dr. Mansoor Ahmad. Karachi-Pakistan.	“Herbal remedy against gastritis”
1499/2007	Dr. Mansoor Ahmad. Karachi-Pakistan.	“Herbal remedy against hepatitis”
1500/2007	AstraZeneca AB. Sweden.	“Novel Compound”

	Priority (21-12-06 USA)	
1501/2007	AstraZeneca AB. Sweden. Priority (21-12-06 USA)	“Novel crystalline compound”
1502/2007	1. Astex Therapeutics Ltd. 2. The Institute of Cancer Research:Royal Cancer Hospital. 3. Cancer Research Technology Limited. 4. AstraZeneca AB. United Kingdom. Priority (21-12-06 UK)	“Substituted piperidines having protein kinase inhibiting activity”
1503/2007	Bayer Schering Pharma Aktiengesellschaft. Germany. Priority (21-12-06 Germany)	“Non-steroidal progesterone receptor modulators”
1504/2007	Plexxikon, Inc. USA. Priority (21-12-06 USA)	“Compounds and methods for kinase modulation, and indications therefore”
1505/2007	Bayer Schering Pharma Aktiengesellschaft. Germany. Priority (21-12-06 Germany)	“Non-steroidal progesterone receptor modulators”
1506/2007	1. Astex Therapeutics Ltd. 2. The Institute of Cancer Research:Royal Cancer Hospital. 3. Cancer Research Technology Ltd. 4. AstraZeneca AB. United Kingdom. Priority (21-12-06 UK)	“Substituted piperidines containing a heteroarylamine or heteroarylphenyl moiety”
1507/2007	Glaxo Group Ltd. United Kingdom. Priority (20-12-06 USA)	“Compounds”
1508/2007	AstraZeneca AB. Sweden. Priority (19-12-06 USA)	“New Compounds 612”
1509/2007	1.AstraZeneca AB. Sweden. 2.Astrex Therapeutics Ltd. United Kingdom Priority (20-12-06 USA)	“New Compounds 617”
1510/2007	1.AstraZeneca AB. Sweden. 2.Bayer Schering Pharma Aktiengesellschaft	“Chemical Compounds 572”

	Germany Priority (21-12-06 USA)	
1511/2007	Banyu Pharmaceutical Co. Ltd. Japan. Priority (28-12-06 Japan)	“Novel aminopyrimidine derivatives as plk1 inhibitors”
1512/2007	DyStar Textilfarben GmbH & Co. Deutschland KG. Germany. Priority (21-12-06 GB)	“Disperse dyes mixtures”
1513/2007	Glaxo Group Limited. United Kingdom. Priority (21-12-06 GB)	“Compounds”
1514/2007	Basf Aktiengesellschaft. Germany. Priority (21-12-06 USA)	“Substituted 1-(azolin-2-yl)-amino-1,2-heterocycl-ethane compounds”
1515/2007	Abbott Laboratories. USA. Priority (21-12-06 USA)	“Sphingosine-1-phosphate receptor agonist and antagonist compounds”
1516/2007	1.AstraZeneca AB. Sweden. 2.Astrex Therapeutics Ltd. United Kingdom Priority (20-12-06 USA)	“New Compounds 620”
1517/2007	AstraZeneca AB. Sweden. Priority (20-12-06 USA)	“Novel compounds 569”
1518/2007	Danisco US, Inc. USA. Priority (18-12-06 USA)	“Novel laccases, compositions and methods of use”
1519/2007	Danisco US, Inc. USA. Priority (18-12-06 USA)	“Laccase mediators and methods of use”
	<u>19-12-2007</u>	
1520/2007	Raytheon Company. USA. Priority 22-12-06 USA)	“Methods and apparatus for a cable retractor to prevent cable damage after connector release”
1521/2007	AstraZeneca AB. Sweden. Priority (20-12-06 USA)	“Novel compounds 621”
1522/2007	Novartis Vaccines & Diagnostics,	“Quinazolines for PDK1 inhibition”

	Inc. USA. Priority (22-12-06 USA)	
1523/2007	Gruene-Bioraffinerie. AT GmbH. Austria. Priority (19-12-06 Austria)	“Process for the treatment of a stream of substances”
1524/2007	Bristol-Myers Squibb Company. USA. Priority (20-12-06 USA)	“Macrocyclic factor VIIA inhibitors useful as anticoagulants”
1525/2007	Saudi Basic Industries Corporation. Saudi Arabia. Priority (21-12-06 EP)	“Process for preparing aromatic polycarboxylic by liquid phase oxidation”
1526/2006	Astex Therapeutics Limited. United Kingdom. Priority (22-12-06 GB)	“New compounds”
1527/2007	Urea Casale S.A. Switzerland. Priority (22-12-06 EP)	“Fluid bed granulation process”
1528/2007	Wyeth. USA. Priority (21-12-06 USA)	“Synthesis of pyrrolidine compounds”
1529/2007	Bayer HealthCare AG. Germany. Priority (22-12-06 EP)	“Production and use of non-native variants of domain 2 of human placental bikunin designed by directed molecular evolution”
1530/2007	Bayer HealthCare AG. Germany. Priority (22-12-06 EP)	“Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene”
1531/2007	Britesoft Solutions (M) SDN BHD Malaysia. Priority (03-10-07 Malaysia).	“Customizable application system”
1532/2007	Zarar Ahmed, Sialkot, Pakistan	“Vector power system (VPS)”
1533/2007	Zarar Ahmed International Lahore, Pakistan	“Integral damping system”
1534/2007	Honda Motor Co. Ltd. Japan. Priority (22-02-07 Japan)	“Front body cover structure for motorcycle”
1535/2007	Merck & Co. Inc. USA.	“A pharmaceutically acceptable salt or solvate of a pyridine-3-carboxylic acid-derived compound for

	Priority 28-06-05 USA) Divisional	use as a pharmaceutical”
1536/2007	Novartis AG. Switzerland. Priority (22-12-06 EP)	“Solid dispersion of a neurokinin antagonist”
1537/2007	Sanofi-Aventis. France. Priority (28-12-06 France)	“Novel therapeutic utilization for the treatment of leukaemias”
1538/2007	Novartis AG. Switzerland. Priority (22-12-06 EP)	“Organic compounds”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

297/1997	Pfizer Inc. USA	“Mesylate dehydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one” (A61K 31/495)
----------	--------------------	---

139336

The invention relates to the mesylate dehydrate salts of 5-(2-(4-(1,2-benzisothiazol-3yl)-1-piperazinyl)-6-chloro-1,3-dihydro-2h-indol-2one, pharmaceutical composition containing said mesylate dehydrate salts, and methods of using said mesylate dehydrate salts to treat psychotic disorder.

300/2005 Telenor ASA,
Norway

“Subscriber identity module for a mobile
communication terminal ”

(HO4M 17/02, HO4M 1/00)

139337

The invention relates to a subscriber identity module for a mobile communication terminal, comprising a processing device, a memory device, an I/O device and a wireless communication device, in particular and interrogatable transponder such as an RFID transponder. The RFID transponder is operatively controllable by said processing device, and comprises a memory which contents identification data, configurable by the processing device. The RFID-enabled subscriber identification module may be used as an authentication token. A method for providing secure communications between the subscriber identification module and an RFID interrogating device is also provided.



(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488